Close Menu

NEW YORK – During a webcast presentation on Tuesday, executives from Pfizer updated market analysts on its oncology R&D pipeline, which includes several drugs for biomarker-defined populations headed for pivotal registration studies, as well as first-in-class agents in preclinical or early-phase clinical studies. 

Among drugs in late-phase development, Pfizer's Oncology Chief Development Officer Chris Boshoff highlighted data on the BRAF- and MEK-targeting agents encorafenib (Braftovi) and binimetinib (Mektovi), as well as the PARP inhibitor talazoparib (Talzenna). 

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Sponsored by

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.